Abstracts tagged "psoriasis"

Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting
The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Lauren Harter¹, Daniel Shin², Joshua F. Baker³, Junko Takeshita², Thorvardur Love^4,5, Joel Gelfand⁶ and Alexis Ogdie⁷, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵Landspitali University Hospital, Reykjavík, Iceland, ⁶University of Pennsylvania Health System , Philadelphia, PA, ⁷Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…
Abstract Number: 7L • 2015 ACR/ARHP Annual Meeting
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015
Laura C Coates^1,2, Arthur Kavanaugh³, Philip J. Mease⁴, Enrique R. Soriano⁵, M Laura Acosta-Felquer⁶, April W Armstrong⁷, Wilson Bautista-Molano⁸, Wolf-Henning Boehncke⁹, Willemina Campbell¹⁰, Alberto Cauli¹¹, Luis Espinoza¹², Oliver FitzGerald¹³, Dafna D. Gladman¹⁴, Alice B. Gottlieb¹⁵, Philip S. Helliwell², M. Elaine Husni¹⁶, Thorvardur Love^17,18, Ennio Lubrano¹⁹, Neil J McHugh²⁰, Peter Nash²¹, Alexis Ogdie-Beatty²², Ana-Maria Orbai²³, Andrew Parkinson²⁴, Denis O'Sullivan²⁵, Cheryl F Rosen²⁶, Sergio Schwartzman²⁷, Evan Siegel²⁸, Sergio Toloza²⁹, William Tuong³⁰ and Christopher T. Ritchlin³¹, ¹Medicine, University of Rochester, Rochester, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁸Department of Rheumatology, Faculty of Medicine HMC/UMNG, Bogota, Colombia, Bogotá, Colombia, ⁹Department of Dermatology,, Geneva University Hospital, Geneva, Switzerland, ¹⁰Toronto Western Hospital, Toronto, ON, Canada, ¹¹University of Cagliari, Cagliari, Italy, ¹²Medicine-Section of Rheumatology, LSU Medical Center, New Orleans, LA, ¹³Department of Rheumatology, St. Vincent’s University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Tufts Medical Center, Boston, MA, ¹⁶Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ¹⁷Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁸Landspitali University Hospital, Reykjavík, Iceland, ¹⁹Cattedra di Reumatologia, Università del Molise, Campobasso, Italy, ²⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²¹Department of Medicine, University of Queensland, Brisbane, Australia, ²²Medicine/Rheumatology, Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ²³Rheumatology, Johns Hopkins University, Baltimore, MD, ²⁴Chapel Allerton Hospital, Leeds, United Kingdom, ²⁵St. Vincent’s University Hospital, Dublin, Ireland, ²⁶Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²⁷Rheumatology, Hospital for Special Surgery, New York, NY, ²⁸Arthritis & Rheumatism Assoc, Wheaton, MD, ²⁹Rheumatology, Ministry of Health, San Fernando del Valle de Catamarca, Argentina, ³⁰Department of Dermatology, University of California David, Davis, CA, ³¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Since the 2009 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably. We updated and improved…
Abstract Number: 2886 • 2015 ACR/ARHP Annual Meeting
Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis
Philip J. Mease¹, Iain B. McInnes², Alice B. Gottlieb³, Albert Widmer⁴, Luminita Pricop⁵ and Shephard Mpofu⁴, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Dermatology, Tufts Medical Center, Boston, MA, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been shown to improve the signs and symptoms of psoriasis and psoriatic arthritis (PsA).1–3 Here, we…
Abstract Number: 3118 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry
Philip J. Mease^1,2,3,4, Chitra Karki⁵, Carol J. Etzel^5,6, Arthur Kavanaugh⁷, Christopher T. Ritchlin⁸, Wendi Malley⁵, Vivian Herrera⁹, Jacqueline B. Palmer⁹ and Jeffrey D. Greenberg^5,10, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Seattle Rheumatology Associates, Seattle, WA, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Clinical Professor, University of Washington School of Medicine, Seattle, WA, ⁵Corrona, LLC, Southborough, MA, ⁶University of Texas M.D. Anderson Cancer Center, Houston, TX, ⁷University of California San Diego, La Jolla, CA, ⁸Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰NYU School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is commonly comorbid with the skin condition, psoriasis. A major contributor to the severity…
Abstract Number: 3119 • 2015 ACR/ARHP Annual Meeting
The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Alexis Ogdie-Beatty¹, Daniel Shin², Junko Takeshita², Zelma ChiesaFuxench² and Joel Gelfand³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Health System , Philadelphia, PA
Background/Purpose: Venous thromboembolism (VTE), the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially deadly medical problem with…
Abstract Number: 3120 • 2015 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Kashif Jafri¹, Christie M. Bartels², Daniel Shin³ and Alexis Ogdie-Beatty⁴, ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Pennsylvania, Philadelphia, PA, ⁴Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) are associated with an increased risk for cardiovascular disease (CVD). While management of traditional CVD risk…
Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Nan Bing¹, HuanYu Zhou¹, BaoHong Zhang¹, John D Bradley², Makoto Nagaoka³, Hernan Valdez⁴, Michael Vincent¹ and James D. Clark¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
Abstract Number: 3234 • 2015 ACR/ARHP Annual Meeting
Roadblocks Perceived By Canadian Dermatologists for Referring Patients with Suspected Psoriatic Arthritis
Renise Ayearst¹, Daniel Pereira¹, Charles Lynde², Holly Etchegary³ and Vinod Chandran¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Memorial University of Newfoundland, St.John's, NF, Canada
Background/Purpose: The current system of referral by Canadian dermatologists of patients who may have psoriatic arthritis (PsA) to rheumatologists is suboptimal. Hypothesizing that knowledge level,…
Abstract Number: 649 • 2015 ACR/ARHP Annual Meeting
Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects?
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Amit Chhabra⁴, Heather Jones⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

Background/Purpose: Psoriatic Arthritis Quality of Life (PsAQol), Ankylosing Spondylitis Quality of Life (ASQoL), and Dermatology Life Quality Index (DLQI) are tools that assess different aspects of health-related…
Abstract Number: 657 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients
Kiana Vakil-Gilani¹, Alexis Dinno², Neha Garg³ and Atul A. Deodhar⁴, ¹Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ²School of Community Health, Portland State University, Portland, OR, ³Rheumatology, Oregon Health and Science University, Portland, OR, ⁴Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: PQoL-12 is a validated composite tool (range: 0–120) assessing patients' quality of life in PsO and PsA. RAPID3 is another validated composite index (range:…
Abstract Number: 670 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Lihi Eder¹, Ari Polachek¹, Cheryl Rosen², Vinod Chandran¹, Richard J. Cook³ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Limited information exists about the characteristics of pre-clinical phases of psoriatic arthritis (PsA). We aimed to assess whether the presence and trends in non-specific…
Abstract Number: 688 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Psoriasis and Psoriatic Arthritis with Surgical Weight Loss
Monica Sethi¹, Christine Ren-Fielding², Ana Clara Caminer^3,4, Jose U. Scher⁵ and Soumya M. Reddy⁶, ¹Department of Surgery, Division of Bariatric Surgery, New York University School of Medicine, New York, NY, ²Department of Surgery, New York University School of Medicine, New York, NY, ³Rheumatology, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina, ⁴Rheumatology, Sanatorio Parque, Rosario, Argentina, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Obesity is more prevalent among patients with psoriasis and psoriatic arthritis (PsA). This correlation appears to be related to fat tissue-driven systemic inflammation. Although…
Abstract Number: 979 • 2015 ACR/ARHP Annual Meeting
HLA Class I Genes As Susceptibility Markers of Psoriatic Arthritis in Patients with Psoriasis – a Meta-Analysis
Lihi Eder¹, Fatima Abji², Cheryl Rosen³, Muhammad Haroon⁴, Vinod Chandran¹, Rubén Queiro⁵, Shelley Bull⁶, Richard J. Cook⁷, Proton Rahman⁸, Robert Winchester⁹, Oliver FitzGerald¹⁰ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Kerry General Hospital, Tralee, Ireland, ⁵Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁶School of Public Health, Mount Sinai Hospital, Toronto, ON, Canada, ⁷Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁸Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁹Columbia University, New York, NY, ¹⁰Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Genes that differentiate patients with psoriatic arthritis (PsA) from those with psoriasis alone may serve as markers for the development of PsA in psoriasis…
Abstract Number: 1202 • 2015 ACR/ARHP Annual Meeting
Knowledge and Perception of Cardiovascular Disease Risk in Patients with Psoriatic Disease
Dennis Wong¹, Daniel Pereira², Sutha Shanmugarajah¹, Renise Ayearst², Dafna Gladman², Cheryl Rosen³ and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The prevalence of cardiovascular diseases (CVD) is higher in patients with psoriatic disease. Psoriatic disease is known to be an independent risk factor for…
Abstract Number: 1718 • 2015 ACR/ARHP Annual Meeting
Entheseal Abnormalities and Nail Involvement at the Distal Interphalangeal Joints on Ultrasound Examination in Patients with Psoriasis and Psoriatic Arthritis. Could the Nail-Enthesitis Theory be Supported?
M Laura Acosta-Felquer¹, Erika Catay², Leandro Ferreyra-Garrot³, Santiago Ruta¹, David A. Navarta⁴, Javier Rosa⁵, Ricardo Galimberti⁶, Maria L. Galimberti⁶, Ricardo Garcia-Monaco⁷ and Enrique R. Soriano⁸, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio,, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Internal Medicine, Argentina, Buenos Aires, Argentina, ⁴Internal Medicine, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Dermatology Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: It has been shown that nail involvement in psoriasis is associated with systemic enthesopathy. The association of enthesopathy and nail disease at distal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].